PRIMARY STUDY
Cannabidiol and Amisulpride Improve Cognition in Acute Schizophrenia in an Explorative, Double-Blind, Active-Controlled, Randomized Clinical Trial
Key Findings: Cannabidiol (CBD) and amisulpride (AMI) (an antiemetic and antipsychotic medication) both improved neurocognitive functioning independently and with similar efficacy in patients with acute schizophrenia.
Type of Study: Double Blind Clinical Trial
Study Sample Size: 42
Study Result: Positive
Research Location(s): Australia, Germany
Year of Pub: 2021
Cannabinoids Studied: Cannabidiol (CBD), Anandamide (AEA)
Phytocannabinoid Source: Unspecified
Chemotype: Chemotype III
Dosage: CBD (800 mg/day)
Route of Administration: Oral (Ingestion)
Citation: Leweke FM, et al. Cannabidiol and Amisulpride Improve Cognition in Acute Schizophrenia in an Explorative, Double-Blind, Active-Controlled, Randomized Clinical Trial. Front Pharmacol. 2021; 12:614811. doi: 10.3389/fphar.2021.614811
Authors: Leweke FM, Rohleder C, Gerth CW, Hellmich M, Pukrop R, Koethe D
